Clinical Trial Update: Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2A trial evaluating PET imaging with 89Zr-Df-IAB2M in metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 89Zr-Df-IAB2M (89Zr-Df-IAB2M)

Snippet

Sponsor: ImaginAb, Inc. | Conditions: Metastatic Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED